Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the
“Company”), a company focused on developing, marketing, and selling
a variety of men’s health and wellness products via a secure
telemedicine platform, including its uniquely formulated hair
growth product (‘GROW’) and erectile dysfunction (ED) drug
(‘Mango’), is excited to announce the highly anticipated release
and availability of ‘PRIME’ by MangoRx, Powered by Kyzatrex®️
(“PRIME”) bringing the FDA-approved oral testosterone replacement
therapy (TRT) treatment to consumers across the U.S via its
proprietary telehealth platform.
MangoRx intends to market PRIME to those male
individuals who are both a) currently on some
alternative form of TRT treatment, such as topicals and other
invasive injectables or pellets, and b) those
experiencing common symptoms associated with low testosterone
(Low-T) and seeking an immediate TRT treatment. Those interested in
speaking with a medical provider to obtain a prescription for PRIME
can do so by visiting MangoRx’s website at
https://www.mangorx.com/app/prime.
According to a study published in the National
Library of Medicine which examined prescribing patterns in the
United States, approximately 2.9% of men aged greater than 40 years
old and 3.75% of men aged greater than 60 years old have been
prescribed with some form of TRT. With the US population of men at
approximately 166.7 million, this places the current market at
roughly 5,000,000 men that are on some form of TRT therapy.
Furthermore, the introduction of oral
testosterone therapy presents a compelling opportunity to tap into
a significant addressable market. By offering an alternative to
injectable TRT, oral therapy addresses the concerns of individuals
who are hesitant or unwilling to undergo injections. This segment
of the market, encompassing those with needle aversion, represents
a substantial portion of the population and presents a compelling
case for the viability and potential growth of oral testosterone
therapy.Jacob Cohen, MangoRx’s Co-Founder and CEO, noted, “We
firmly believe that between the convenience and non-invasive factor
of taking PRIME orally and the reduced side effects that come with
it as opposed to traditional injectable TRT, MangoRx is very well
positioned to grab a significant piece of the current market share
for men experiencing Low-T. As we believe PRIME’s oral delivery TRT
treatment is a true game-changer, MangoRx will be seeking to engage
popular social media influencers as well as high-profile
celebrities and athletes to assist us as we launch PRIME into the
marketplace.”
PRIME represents a critical expansion into a new
vertical with massive market potential and very little competition
on the consumer side, while remaining completely consistent with
MangoRx’s established identity as a company committed to providing
new and innovative pharmaceutical based solutions helping men
achieve optimal performance in all areas of life. With the
Company’s established marketing and telemedicine infrastructure in
place, MangoRx is hitting the ground running to take PRIME to
patients in need across the country. All orders will be reviewed
and, pending approval, fulfilled, then discreetly shipped via
MangoRx’s URAC accredited mail order partner pharmacy directly to
the patient’s doorstep.
About PRIME
‘PRIME’, by MangoRx, powered by Kyzatrex®️, an
innovative FDA-approved oral Testosterone Replacement Therapy (TRT)
product, is a prescription drug that is used to treat adult men who
have low or no testosterone levels due to certain medical
conditions and is one of only three FDA approved TRT treatments
that is delivered orally--as opposed to the traditional, invasive,
and inconvenient injection-based drug delivery protocol. ‘PRIME’,
by MangoRx, powered by Kyzatrex®️ delivers testosterone in a
softgel capsule that is absorbed primarily via the lymphatic
system, avoiding liver toxicity.
The benefits of ‘PRIME,’ powered by Kyzatrex®️,
over traditional injectable TRTs include enhanced vitality,
improved mood, sharper cognition, optimized physical performance,
and balanced hormonal levels at 96% efficacy by day 90, as
demonstrated in Phase 3 clinical research by Marius
Pharmaceuticals. With ‘PRIME,’ MangoRx will expand broad-based
consumer access to this revolutionary therapy. PRIME is available
to MangoRx customers at a price of $249/month with eligibility to
receive an additional 10% discount per month if subscribed to
another MangoRx product (e.g. ‘Mango’ for erectile function or
‘Grow’ for hair growth).
To learn more about PRIME, please visit
https://www.mangorx.com/app/prime for more information.
About MangoRx
MangoRx is focused on developing a variety of
men's health and wellness products and services via a secure
telemedicine platform. To date, the Company has identified men's
wellness telemedicine services and products as a growing sector and
especially related to the area of erectile dysfunction (ED), hair
growth and hormone replacement therapies. Interested consumers can
use MangoRx’s telemedicine platform for a smooth experience.
Prescription requests will be reviewed by a physician and, if
approved, fulfilled and discreetly shipped through MangoRx’s
partner compounding pharmacy and right to the patient’s
doorstep.
To learn more about MangoRx’s mission and other
products, please visit www.MangoRx.com or on social media
@Mango.Rx.
Cautionary Note Regarding
Forward-Looking Statements
Certain statements made in this press release
contain forward-looking information within the meaning of
applicable securities laws, including within the meaning of the
Private Securities Litigation Reform Act of 1995 ("forward-looking
statements"). These forward-looking statements represent the
Company's current expectations or beliefs concerning future events
and can generally be identified using statements that include words
such as "estimate," "expects," "project," "believe," "anticipate,"
"intend," "plan," "foresee," "forecast," "likely," "will," "target"
or similar words or phrases. These forward-looking statements are
subject to risks, uncertainties and other factors, many of which
are outside of the Company's control which could cause actual
results to differ materially from the results expressed or implied
in the forward-looking statements, including, but not limited to;
our ability to obtain additional funding and generate revenues to
support our operations; risks associated with our ED product which
have not been, and will not be, approved by the U.S. Food and Drug
Administration ("FDA") and have not had the benefit of the FDA's
clinical trial protocol which seeks to prevent the possibility of
serious patient injury and death; risks that the FDA may determine
that the compounding of our planned products does not fall within
the exemption from the Federal Food, Drug, and Cosmetic Act ("FFDCA
Act") provided by Section 503A; risks associated with related party
relationships and agreements; the effect of data security breaches,
malicious code and/or hackers; competition and our ability to
create a well-known brand name; changes in consumer tastes and
preferences; material changes and/or terminations of our
relationships with key parties; significant product returns from
customers, product liability, recalls and litigation associated
with tainted products or products found to cause health issues; our
ability to innovate, expand our offerings and compete against
competitors which may have greater resources; our significant
reliance on related party transactions; the projected size of the
potential market for our technologies and products; risks related
to the fact that our Chairman and Chief Executive Officer, Jacob D.
Cohen and President, Jonathan Arango, combined have majority voting
control over the Company; risks related to the significant number
of shares in the public float, our share volume, the effect of
sales of a significant number of shares in the marketplace, and the
fact that the majority of our shareholders paid less for their
shares than the public offering price of our common stock in our
recent initial public offering; the fact that we have a significant
number of outstanding warrants to purchase shares of common stock
at $1.00 per share, the resale of which underlying shares have been
registered under the Securities Act of 1933, as amended; our
ability to build and maintain our brand; cybersecurity, information
systems and fraud risks and problems with our websites; changes in,
and our compliance with, rules and regulations affecting our
operations, sales, marketing and/or our products; shipping,
production or manufacturing delays; regulations we are required to
comply with in connection with our operations, manufacturing,
labeling and shipping; our dependency on third-parties to prescribe
and compound our ED product; our ability to establish or maintain
relations and/or relationships with third-parties; potential safety
risks associated with our Mango ED product, including the use of
ingredients, combination of such ingredients and the dosages
thereof; the effects of high inflation, increasing interest rates
and economic downturns, including potential recessions, as well as
macroeconomic, geopolitical, health and industry trends, pandemics,
acts of war (including the ongoing Ukraine/Russian conflict) and
other large-scale crises; our ability to protect intellectual
property rights; our ability to attract and retain key personnel to
manage our business effectively; our ability to maintain the
listing of our common stock on the Nasdaq Capital Market; overhang
which may reduce the value of our common stock; volatility in the
trading price of our common stock; and general consumer sentiment
and economic conditions that may affect levels of discretionary
customer purchases of the Company's products, including potential
recessions and global economic slowdowns. Although we believe that
our plans, intentions and expectations reflected in or suggested by
the forward-looking statements we make in this release are
reasonable, we provide no assurance that these plans, intentions or
expectations will be achieved. Consequently, you should not
consider any such list to be a complete set of all potential risks
and uncertainties.
More information on potential factors that could
affect the Company's financial results is included from time to
time in the "Cautionary Note Regarding Forward-Looking Statements,"
"Risk Factors" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" sections of the
Company's filings with the SEC, including the Company’s Quarterly
Report on Form 10-Q for the Quarter ended September 30, 2023. These
filings are available at www.sec.gov and at our website at
https://www.mangoceuticals.com/sec-filings. All subsequent written
and oral forward-looking statements attributable to the Company or
any person acting on behalf of the Company are expressly qualified
in their entirety by the cautionary statements referenced above.
Other unknown or unpredictable factors also could have material
adverse effects on the Company's future results. The
forward-looking statements included in this press release are made
only as of the date hereof. The Company cannot guarantee future
results, levels of activity, performance or achievements.
Accordingly, you should not place undue reliance on these
forward-looking statements. Finally, the Company undertakes no
obligation to update these statements after the date of this
release, except as required by law, and takes no obligation to
update or correct information prepared by third parties that are
not paid for by the Company. If we update one or more
forward-looking statements, no inference should be drawn that we
will make additional updates with respect to those or other
forward-looking statements.
Follow Mangoceuticals and MangoRx on social media:
https://www.instagram.com/mango.rx
https://twitter.com/Mangoceuticals
https://www.facebook.com/MangoRxOfficial
FOR PUBLIC RELATIONSLucky Break Public RelationsSahra
SimpsonSahra@luckybreakpr.com(323) 602-0091 ext. 704
FOR INVESTOR RELATIONSMangoceuticals Investor RelationsEmail:
investors@mangorx.com
MEDIA CONTACTPHOENIX MGMT Marketing &
Consultinginfo@phoenix-mediamarketing.com
SOURCE: Mangoceuticals Inc.
Mangoceuticals (NASDAQ:MGRX)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Mangoceuticals (NASDAQ:MGRX)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024